Eva Laker

1.1k total citations
23 papers, 162 citations indexed

About

Eva Laker is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Eva Laker has authored 23 papers receiving a total of 162 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 7 papers in Virology and 7 papers in Epidemiology. Recurrent topics in Eva Laker's work include HIV/AIDS Research and Interventions (11 papers), HIV/AIDS drug development and treatment (10 papers) and HIV Research and Treatment (7 papers). Eva Laker is often cited by papers focused on HIV/AIDS Research and Interventions (11 papers), HIV/AIDS drug development and treatment (10 papers) and HIV Research and Treatment (7 papers). Eva Laker collaborates with scholars based in Uganda, United Kingdom and United States. Eva Laker's co-authors include Mohammed Lamorde, Rosalind Parkes‐Ratanshi, Barbara Castelnuovo, Melanie R. Nicol, Joshua Rhein, Kay Seden, Anna Stadelman, Nicole Engen, David R. Boulware and Agnes Kiragga and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy and British Journal of Clinical Pharmacology.

In The Last Decade

Eva Laker

20 papers receiving 162 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eva Laker Uganda	6	112	55	43	25	21	23	162
Lindsey Powers Happ United States	6	110 1.0×	64 1.2×	40 0.9×	26 1.0×	40 1.9×	11	147
Nicole Dear United States	8	126 1.1×	33 0.6×	57 1.3×	57 2.3×	35 1.7×	24	187
Juan Pasquau Liaño Spain	6	137 1.2×	78 1.4×	60 1.4×	16 0.6×	22 1.0×	14	184
D. Tumukunde Uganda	4	103 0.9×	61 1.1×	46 1.1×	18 0.7×	26 1.2×	7	133
Adeola Adeyeye United States	8	112 1.0×	54 1.0×	23 0.5×	38 1.5×	43 2.0×	17	163
Joseph Lutaakome Uganda	6	130 1.2×	58 1.1×	81 1.9×	53 2.1×	10 0.5×	10	205
Iorhen E. Akase Nigeria	7	113 1.0×	56 1.0×	12 0.3×	12 0.5×	13 0.6×	26	191
R. Nalumenya United Kingdom	3	96 0.9×	57 1.0×	42 1.0×	13 0.5×	23 1.1×	5	124
Jeremy Ross Thailand	10	163 1.5×	78 1.4×	67 1.6×	61 2.4×	29 1.4×	31	216
Thomas Finkbeiner United States	6	178 1.6×	63 1.1×	19 0.4×	104 4.2×	50 2.4×	7	206

Countries citing papers authored by Eva Laker

Since Specialization

Citations

This map shows the geographic impact of Eva Laker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Laker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Laker more than expected).

Fields of papers citing papers by Eva Laker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Laker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Laker. The network helps show where Eva Laker may publish in the future.

Co-authorship network of co-authors of Eva Laker

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Laker. A scholar is included among the top collaborators of Eva Laker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Laker. Eva Laker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laker, Eva, Melanie R. Nicol, Allan Buzibye, et al.. (2025). A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda. HIV Medicine. 26(4). 592–605. 1 indexed citations

Buzibye, Allan, Barbara Castelnuovo, Robert C. Bollinger, et al.. (2025). Dolutegravir-associated hyperglycemia: a narrative review. AIDS Research and Therapy. 22(1). 93–93.

Laker, Eva, et al.. (2025). Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa. International Health. 17(5). 695–700. 1 indexed citations

Waitt, Catriona, et al.. (2024). Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa. British Journal of Clinical Pharmacology. 90(9). 2079–2091. 4 indexed citations

Laker, Eva, et al.. (2024). Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda. AIDS Research and Therapy. 21(1). 23–23. 2 indexed citations

Zawedde‐Muyanja, Stella, Barbara Castelnuovo, Ahmed Ddungu, et al.. (2024). Private pharmacy and community health worker engagement in the provision of TB services. The International Journal of Tuberculosis and Lung Disease. 28(7). 343–347. 1 indexed citations

Schwarz, Jean‐Marc, Nele Brusselaers, Robert C. Bollinger, et al.. (2024). Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks. BMC Infectious Diseases. 24(1). 746–746.

Sekaggya‐Wiltshire, Christine, Jonathan Mayito, Eva Laker, et al.. (2024). Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol. BMJ Open. 14(12). e088389–e088389.

Castelnuovo, Barbara, Nele Brusselaers, Robert C. Bollinger, et al.. (2023). Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults. AIDS Research and Therapy. 20(1). 65–65. 3 indexed citations

10.

Castelnuovo, Barbara, Nele Brusselaers, Robert C. Bollinger, et al.. (2023). Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir. AIDS Research and Therapy. 20(1). 15–15. 15 indexed citations

11.

Laker, Eva, Fiona V Cresswell, Mohammed Lamorde, et al.. (2022). High willingness to use injectable antiretroviral therapy among women who have been lost to follow‐up from HIV programmes: A nested cross‐sectional study. HIV Medicine. 23(4). 319–323. 4 indexed citations

12.

Kiwanuka, Suzanne N., Juliet Kiguli, Eva Laker, et al.. (2022). Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda. BMC Women s Health. 22(1). 262–262. 4 indexed citations

13.

Laker, Eva, et al.. (2022). Prevalence of overweight and obesity and associated factors among people living with HIV attending a tertiary care clinic in Uganda. BMC Nutrition. 8(1). 107–107. 12 indexed citations

14.

Byonanebye, Dathan M., Agnes Bwanika Naggirinya, Mohammed Lamorde, et al.. (2021). An Interactive Voice Response Software to Improve the Quality of Life of People Living With HIV in Uganda: Randomized Controlled Trial. JMIR mhealth and uhealth. 9(2). e22229–e22229. 24 indexed citations

15.

Katamba, Achilles, Eva Laker, Peter Lochoro, et al.. (2021). The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study. BMC Infectious Diseases. 21(1). 950–950. 4 indexed citations

16.

Laker, Eva, et al.. (2020). The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women. Drug Safety. 43(11). 1133–1140. 5 indexed citations

17.

Laker, Eva, Arvind Kaimal, Barbara Castelnuovo, et al.. (2019). An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir. BMC Infectious Diseases. 19(1). 280–280. 2 indexed citations

18.

Seden, Kay, Concepta Merry, Russ Hewson, et al.. (2015). Prevalence and type of drug–drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. Journal of Antimicrobial Chemotherapy. 70(12). dkv259–dkv259. 18 indexed citations

19.

Laker, Eva, et al.. (2014). Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala. Journal of the International AIDS Society. 17(4S3). 19792–19792. 5 indexed citations

20.

Seden, Kay, Catherine L.R. Merry, Mohammed Lamorde, et al.. (2012). Prevalence and type of drug‐drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda. Journal of the International AIDS Society. 15(S4). 1–1. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact